Publication | Open Access

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial

Anti-inflammatoryGouty ArthritisPharmacologyClinical TrialsPharmacotherapyInnovative TreatmentMedicineGout FlaresNovel TherapyRheumatoid ArthritisDrug Discovery